Advancing antisolvent membrane crystallisation

Reverse anti-solvent membrane crystallisation can produce the submicron sized drug particles required for long-acting injectable formulations through the unparalleled control of solvent mixing that is both precise and scalable. This disruptive technology mitigates the solid-state changes and particle size variability associated with historic drug production approaches to catalyse the development and manufacture of long-acting injectable medicines that are critically important to a wide range of treatments. The role of solvent and drug properties will first be examined to understand how to control the metastable region (and hence the kinetics of crystallisation) and will be complemented with examination of hydrodynamics which is relevant to defining conditions that control particle size and particle size distribution.